Guggenheim Downgrades Altimmune to Neutral
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Seamus Fernandez downgrades Altimmune (NASDAQ:ALT) from Buy to Neutral, indicating a shift in the investment firm's outlook on the company.

April 29, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Altimmune's stock rating was downgraded by Guggenheim from Buy to Neutral, reflecting a more cautious view on the company's future performance.
Analyst downgrades typically lead to a negative short-term impact on the stock price as they suggest a less optimistic outlook on the company's future performance and profitability. Given the downgrade is from Buy to Neutral, it indicates a significant shift in confidence from a positive to a more cautious stance, likely influencing investor sentiment and potentially leading to a decrease in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100